Company Encyclopedia
View More
name
Nanobiotix SA
NBTX.US
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
1.876 T
NBTX.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking215/389
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE113.84%A
    • Profit Margin-508.35%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-75.38%E
    • Net Profit YoY-57.81%D
    • Total Assets YoY-43.05%E
    • Net Assets YoY-245.98%E
  • Cash ScoreE
    • Cash Flow Margin-19.67%D
    • OCF YoY-75.38%E
  • Operating ScoreD
    • Turnover0.15D
  • Debt ScoreE
    • Gearing Ratio252.64%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nanobiotix SA Reports Update on Issued Shares and Voting Rights

    Nanobiotix SA announced that as of October 31, 2025, it had 48,237,471 shares outstanding, with 50,267,962 theoretical voting rights and 50,245,844 exercisable voting rights. This update was published via GlobeNewswire on November 14, 2025.

    Reuters·
    US
    NBTX
    +2.61%
    Reuters·
    US
    NBTX
    +2.61%

    Nanobiotix Unveils Preclinical Proof-of-Concept for Curadigm Nanoprimer in Cancer Treatment

    Nanobiotix SA has announced promising preclinical results for its Curadigm Nanoprimer platform in cancer treatment. The in vivo data, presented at the 2025 PODD conference, establish proof-of-concept for the platform's potential applications. The company has also filed four new patent applications to expand its intellectual property portfolio. This news was originally published by Nanobiotix SA via GlobeNewswire on November 13, 2025.

    Reuters·
    US
    NBTX
    +2.61%
    Reuters·
    US
    NBTX
    +2.61%

    Nanobiotix SA to Participate in Jefferies London Healthcare Conference

    Nanobiotix SA will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2025. CEO Laurent Levy and CFO Bart van Rhijn will present, and the session will be webcast live on the company’s website with a replay available afterward. This announcement was published via GlobeNewswire on November 11, 2025.

    Reuters·
    US
    NBTX
    +2.61%
    Reuters·
    US
    NBTX
    +2.61%

    Nanobiotix SA to Participate in Major Investor Conferences

    Nanobiotix SA will participate in several investor conferences during the week of November 10, 2025. CEO Laurent Levy and CFO Bart van Rhijn will present at the UBS Global Healthcare Conference and the Guggenheim Annual Healthcare Innovation Conference on November 10, and at the Stifel Healthcare Conference on November 13. The company focuses on nanotherapeutic approaches for cancer and other diseases, and recordings of the presentations will be available on its website.

    Reuters·
    US
    NBTX
    +2.61%
    Reuters·
    US
    NBTX
    +2.61%

    Nanobiotix Secures Up to $71 Million in Royalty Financing from HealthCare Royalty

    Nanobiotix SA has secured up to $71 million in non-dilutive financing through a royalty monetization agreement with Healthcare Royalty (HCRx). The deal includes an upfront payment of $50 million, with an additional $21 million expected after one year, contingent on certain conditions. The funding will support the advancement of Nanobiotix’s nanotherapeutics platforms and extend its cash runway into early 2028, particularly for head and neck and lung cancer developments. HCRx will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3). TD Cowen acted as the financial advisor.

    Reuters·
    US
    NBTX
    +2.61%
    Reuters·
    US
    NBTX
    +2.61%